

Claim Amendments:

Please amend the claims as follows.

1-8 (canceled).

- Rule
1.126
- 15 ~~9~~. (new): A method for treatment of rheumatoid arthritis comprising administering to a subject suffering from rheumatoid arthritis a therapeutically effective amount of an antibody molecule comprising antigen binding regions derived from the light and heavy chain variable regions of an antibody to an $\alpha 1\beta 1$ integrin or fragment thereof.
- 16 ~~10~~. (new): A method for inhibiting or preventing rheumatoid arthritis comprising administering to a subject at risk of developing or suffering from rheumatoid arthritis a therapeutically effective amount of an antibody molecule comprising antigen binding regions derived from the light and heavy chain variable regions of an antibody to an $\alpha 1\beta 1$ integrin or fragment thereof.
- 17 ~~11~~. (new): A method of claim ¹⁵~~9~~, wherein the antibody is AJH10 secreted by a hybridoma designated as ATCC PTA-3580.
- 18 ~~12~~. (new): A method of claim ¹⁶~~10~~, wherein the antibody is AJH10 secreted by a hybridoma designated as ATCC PTA-3580.
- 19 ~~13~~. (new): A method of claim ¹⁵~~9~~, wherein the antibody is a human antibody, a chimeric antibody, a humanized antibody, a monoclonal antibody, or a polyclonal antibody.
- 20 ~~14~~. (new): A method of claim ¹⁶~~10~~, wherein the antibody is a human antibody, a chimeric antibody, a humanized antibody, a monoclonal antibody, or a polyclonal antibody.
- 21 ~~15~~. (new): A method of claim ¹⁵~~9~~, wherein the antibody is an anti- $\alpha 1$ -I domain blocking antibody and the amino acid sequence of the antibody epitope comprises the sequence Val-Gln-Arg-Gly-Gly-Arg (SEQ ID NO: 8) or an amino acid sequence that is equivalent or homologous to such sequence.
- 22 ~~16~~. (new): A method of claim ¹⁶~~10~~, wherein the antibody is an anti- $\alpha 1$ -I domain blocking antibody and the amino acid sequence of the antibody epitope comprises the sequence Val-Gln-Arg-Gly-Gly-Arg (SEQ ID NO: 8) or an amino acid sequence that is equivalent or homologous to such sequence.

Applicants: Gotwals, et al.
Application No.: To Be Assigned
Filed: Herewith
Page 6 of 9

Docket No. A073 USCN2

Rule
1.126

23 ~~PT~~. (new): A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of the antibody AJH10 secreted by a hybridoma designated as ATCC PTA-3580 effective in preventing, inhibiting, or treating rheumatoid arthritis.